SCHEMBL97399

SCHEMBL97399

CC(C)OC(=O)CCCCCO

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.70
MAPT P10636 2/20 0.50
MAPK1 P28482 1/20 0.50
GPR84 Q9NQS5 1/20 0.44
FFAR1 O14842 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
ALDH1A1 P00352 2/20 0.44
GAA P10253 1/20 0.44
EPHX2 P34913 1/20 0.44
PRKCA P17252 2/20 0.43
PRKCE Q02156 1/20 0.43
PRKCQ Q04759 1/20 0.43
PRKCD Q05655 1/20 0.43
KDM4E B2RXH2 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
DUSP3 P51452 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3503764 1.00 LMNA (0.70) LMNAMAPTMAPK1GPR84FFAR1
SCHEMBL1278227 1.00 LMNA (0.70) LMNAMAPTMAPK1GPR84FFAR1
SCHEMBL3503956 1.00 LMNA (0.70) LMNAMAPTMAPK1GPR84FFAR1
SCHEMBL28284361 1.00 LMNA (0.70) LMNAMAPTMAPK1GPR84FFAR1
SCHEMBL3504067 1.00 LMNA (0.70) LMNAMAPTMAPK1GPR84FFAR1
SCHEMBL3505201 0.98 LMNA (0.67) LMNAMAPTMAPK1GPR84FFAR1
Isopropyl Myristate SCHEMBL10717490 0.92 LMNA (0.85) LMNAMAPTMAPK1ALDH1A1PRKCA
Isopropyl Myristate SCHEMBL5513841 0.92 LMNA (0.85) LMNAMAPTMAPK1ALDH1A1PRKCA
Cetyl Alcohol SCHEMBL753660 0.92 LMNA (0.85) LMNAMAPTMAPK1ALDH1A1PRKCA
Isopropyl Myristate SCHEMBL10382139 0.92 LMNA (0.85) LMNAMAPTMAPK1ALDH1A1PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114044886-B Production method of polycaprolactone 青岛科技大学 2023-08-29 CN claimed
CN-114044886-A Production method of polycaprolactone 青岛科技大学 2022-02-15 CN claimed
US-20170087154-A1 DRY POWDER FORMULATION OF AZOLE DERIVATIVE FOR INHALATION GALEPHAR PHARMACEUTICAL RESEARCH, INC. (US) 2017-03-30 US claimed
EP-2601973-A1 Dry powder formulation of azole derivative for inhalation Laboratoires SMB SA (BE) 2013-06-12 EP claimed
US-20240209160-A1 POLYMERIC DISPERSANTS FROM PHENYL GLYCIDYL ETHER STEPAN COMPANY 2024-06-27 US disclosed
US-20230399457-A1 Bioactive Synthetic Copolymer, Bioactive Macromolecule and Related Methods Thereof AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2023-12-14 US disclosed
CN-114044886-B Production method of polycaprolactone 青岛科技大学 2023-08-29 CN disclosed
CN-112898264-B Method for preparing epsilon-caprolactone, 6-hydroxycaproic acid and esters thereof by using furan acetic acid and esters thereof 中国科学院兰州化学物理研究所 2022-04-22 CN disclosed
CN-112851623-B Method for preparing epsilon-caprolactone, 6-hydroxycaproic acid and ester thereof by using tetrahydrofurfuryl acetic acid and ester thereof 中国科学院兰州化学物理研究所 2022-04-08 CN disclosed
CN-114044886-A Production method of polycaprolactone 青岛科技大学 2022-02-15 CN disclosed
CN-112898264-A Method for preparing epsilon-caprolactone, 6-hydroxycaproic acid and esters thereof by using furan acetic acid and esters thereof 中国科学院兰州化学物理研究所 2021-06-04 CN disclosed
CN-112851623-A Method for preparing epsilon-caprolactone, 6-hydroxycaproic acid and ester thereof by using tetrahydrofurfuryl acetic acid and ester thereof 中国科学院兰州化学物理研究所 2021-05-28 CN disclosed
WO-1994001113-A1 OXYTOCIN ANTAGONIST OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1994-01-20 WO disclosed
US-5244898-A Vasopressin antagonist OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-09-14 US disclosed
US-5225402-A Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-07-06 US disclosed
EP-0514667-A1 Benzazepin derivatives as vasopressin antagonists OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-11-25 EP disclosed
EP-0513387-A1 ACTIVE OXYGEN INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-11-19 EP disclosed
US-5068361-A Cyclization, deesterification, esterification over a fixed bed or fluidized bed oxidic catalyst BASF AKTIENGESELLSCHAFT (DE) 1991-11-26 US disclosed
EP-0450097-A1 BENZOHETEROCYCLIC COMPOUNDS. OTSUKA PHARMA CO LTD (JP) 1991-10-09 EP disclosed
WO-1991005549-A1 BENZOHETEROCYCLIC COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240209160-A1 POLYMERIC DISPERSANTS FROM PHENYL GLYCIDYL ETHER TYR, PAOX, NAPEPLD LMNA 4466/4885MAPT 1821/4885MAPK1 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.